Breaking News, Collaborations & Alliances

UNION Therapeutics, Innovent Enter Strategic Orismilast Alliance

Innovent gains exclusive license to research, develop and commercialize orismilast in China for atopic dermatitis and psoriasis.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

UNION Therapeutics, a privately-held, clinical stage pharmaceutical company focused on immunology and infectious diseases, and Innovent Biologics Ltd., a biopharmaceutical company that develops, manufactures and commercializes treatments for cancer, metabolic, autoimmune and other major diseases, have entered into a strategic collaboration and license agreement for the development and commercialization of orismilast in China.   Under the agreement, UNION grants Innovent an exclusive license to...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters